PTH - ETF AI Analysis
Top Page
Invesco DWA Healthcare Momentum ETF (PTH)
PTH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 302.68M
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 0.88
- Issuer
- Invesco
- Inception Date
- Oct 12, 2006
- Dividend Yield
- 2.55%
- Asset Class
- Equity
- Index Tracked
- Dorsey Wright Healthcare Tech Leaders TR
PTH Summary
PTH is the Invesco DWA Healthcare Momentum ETF, which follows the Dorsey Wright Healthcare Tech Leaders Index. It focuses on U.S. healthcare companies that have been doing well recently, including areas like biotech, medical devices, and hospital services. Some of its holdings are Tenet Healthcare and 10x Genomics. Investors might consider PTH if they want growth potential from innovative healthcare businesses and a way to spread their money across many companies in this sector. A key risk is that healthcare and biotech stocks can be very volatile, so the value of this ETF can move up and down sharply.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 invested. That’s higher than the average ETF because it uses an actively managed, momentum-based strategy in a specialized sector, which typically costs more than simple index-tracking funds.
What would affect this ETF?
PTH could benefit from ongoing medical innovation, an aging U.S. population, and strong performance in biotech and healthcare services, especially if healthcare spending and supportive regulations continue to grow. On the negative side, the fund is highly concentrated in U.S. healthcare stocks and smaller biotech names, so setbacks in drug approvals, tighter healthcare policies, or market pullbacks that hurt high-momentum growth companies could weigh heavily on future returns.
PTH Top 10 Holdings
PTH is essentially a high-octane bet on U.S. healthcare innovators, with a heavy tilt toward biotech and genomics. Rising names like Medpace and Tenet Healthcare provide a steadier backbone, helped by solid earnings and momentum. Around them, more speculative players such as Iovance, 10x Genomics, and Twist Bioscience are swinging harder, with recent trading looking mixed to lagging despite longer-term momentum. That blend of hospital operators and cutting-edge lab names means the fund’s performance is driven by a concentrated cluster of healthcare disruptors, mostly living and breathing in the U.S. market.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 IOVA | Iovance Biotherapeutics | 4.86% | $14.87M | $3.84B | 334.87% | 50Neutral |
 TXG | 10x Genomics | 3.94% | $12.06M | $9.13B | 463.59% | 60Neutral |
 GH | Guardant Health | 3.84% | $11.75M | $23.99B | 93.49% | 61Neutral |
 NTRA | Natera | 3.80% | $11.62M | $59.72B | 114.42% | 73Outperform |
 ROIV | Roivant Sciences | 3.68% | $11.26M | $26.66B | 88.51% | 58Neutral |
 THC | Tenet Healthcare | 3.60% | $11.01M | $21.75B | 30.98% | 74Outperform |
 RVMD | Revolution Medicines | 3.42% | $10.44M | $41.00B | 224.97% | 52Neutral |
 TWST | Twist Bioscience | 3.29% | $10.06M | $10.06B | 390.15% | 43Neutral |
 MEDP | Medpace Holdings | 3.00% | $9.17M | $18.24B | 12.34% | 79Outperform |
 INSM | Insmed | 2.97% | $9.07M | $24.70B | -42.03% | 43Neutral |
PTH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Positive. The current price of 59.78 is above the 20-day moving average (MA) of 58.76, below the 50-day MA of 60.41, and above the 200-day MA of 54.58, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 50.94 is Neutral, neither overbought nor oversold. The STOCH value of 81.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTH.
PTH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PTH | $59.78 | $64.00(7.06% Upside) | $302.68M | 0.60% | 60Neutral |
 RSPH | $39.69 | $42.51(7.09% Upside) | $991.68M | 0.40% | 71Outperform |
 PJP | $130.54 | $159.85(22.45% Upside) | $575.09M | 0.58% | 70Neutral |
 XPH | $64.80 | $109.32(68.70% Upside) | $466.58M | 0.35% | 56Neutral |
 PINK | $40.62 | $50.39(24.04% Upside) | $335.60M | 0.51% | 65Neutral |
 PSCH | $55.69 | $67.48(21.17% Upside) | $182.03M | 0.29% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PTH | Invesco DWA Healthcare Momentum ETF | 59.78 | 13.14 | 28.17% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.69 | 9.65 | 32.11% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 34.57 | 36.02% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 64.80 | 15.34 | 31.00% | |
| PINK | Simplify Health Care ETF | 40.62 | 7.99 | 24.47% | |
| PSCH | Invesco S&P SmallCap Health Care ETF | 55.69 | 13.32 | 31.44% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.